Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,261.10 -19.24 (-1.50%)

Streaming Delayed Price Updated: 10:25 AM EDT, Aug 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

99 100 Next >

Is Moderna Stock Outperforming the Dow?

March 04, 2026

Moderna has outperformed the Dow over the past year, yet Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Via Barchart.com

Topics Stocks

Eli Lilly & Co (NYSE:LLY): A High-Growth Dividend Stock for Discerning Investors ↗

March 04, 2026

Via Chartmill

Hims Stock Slips Overnight As FDA Warns Telehealth Firms Over GLP-1 Claims — Why Traders Think The ‘Overhang’ Won’t Last ↗

March 04, 2026

The warnings involve compounded versions of Semaglutide, Tirzepatide and Liraglutide, the active ingredients in Wegovy, Ozempic and Mounjaro.

Via Stocktwits

Topics Lawsuit

2 Top Growth Stocks to Buy in the First Half of 2026 ↗

March 03, 2026

A decade from now, you might be very glad you did so.

Via The Motley Fool

Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗

March 03, 2026

Lilly is leading the pack in the GLP-1 race, but this isn't a sprint, and you should consider more than just weight loss drugs.

Via The Motley Fool

Topics Intellectual Property

The Best Healthcare Stock to Invest $1,000 in Right Now ↗

March 02, 2026

There's nothing generic about this drugmaker's recent performance and continued prospects.

Via The Motley Fool

Buying This 1 Pharmaceutical Stock Today Could Make You a Multimillionaire Retiree ↗

March 02, 2026

This stock looks unstoppable right now.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

Why I'm Not Worried About Novo Nordisk Stock ↗

March 02, 2026

The stock is down big of late, but the business is by no means doomed.

Via The Motley Fool

Topics Intellectual Property

Up Over 400% in 5 Years, Is It Too Late to Invest in Eli Lilly Stock? ↗

March 02, 2026

Eli Lilly has been a growth beast in recent years, but its valuation has gotten fairly high along the way.

Via The Motley Fool

Should You Forget Eli Lilly and Buy This Magnificent High-Yield Dividend Stock Instead? ↗

March 01, 2026

Eli Lilly is making headlines in the pharmaceutical sector, but it's a very expensive stock.

Via The Motley Fool

Topics Intellectual Property

The Great Divergence: AI Supremacy Masks a Hidden Bear Market in Healthcare and Industrials

February 27, 2026

The final trading week of February 2026 has laid bare a striking fracture in the U.S. equity markets. While the technology sector continues to feast on a relentless AI-driven "execution" cycle, the...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

The 7,800 Frontier: Morgan Stanley Flips the Script with Bullish S&P 500 Forecast

February 27, 2026

In a dramatic departure from his historically cautious stance, Mike Wilson, Chief U.S. Equity Strategist at Morgan Stanley (NYSE: MS), has stunned Wall Street by raising the firm’s 12-month S&P 500...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

The Lilly Era: How Eli Lilly Transformed into a Trillion-Dollar Healthcare Titan

February 27, 2026

As of late February 2026, the financial narrative of the past two years has been dominated by a singular force in the healthcare sector: Eli Lilly & Company (NYSE: LLY). Once considered a traditional...

Via MarketMinute

Topics Artificial Intelligence ETFs

S&P 500 Crosses Historic 7,000 Milestone: Technical and Psychological Significance of the Breakout

February 27, 2026

In a defining moment for global financial markets, the S&P 500 Index officially breached the 7,000-point mark for the first time in history on January 28, 2026. This monumental achievement underscores...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?

February 27, 2026

Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Via Barchart.com

Topics Stocks

The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026

February 27, 2026

As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the...

Via Finterra

Topics Economy Intellectual Property

OPKO Health (OPK) Q4 2025 Earnings Call Transcript ↗

February 26, 2026

OPKO Health (OPK) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

The Great Recalibration: Investors Pivot from Silicon Dreams to Industrial Reality

February 26, 2026

As the bull market of the mid-2020s enters a more mature and discerning phase, a profound shift is unfolding across global trading floors. The speculative fervor that once propelled "AI darlings" to...

Via MarketMinute

Topics Artificial Intelligence Economy Fraud

Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗

February 26, 2026

The maker of Wegovy hasn't said its last words just yet.

Via The Motley Fool

Why Shares of Novo Nordisk Stock Sank (Again) This Week ↗

February 26, 2026

The weight-loss drug innovator is falling behind in the industry and facing major pricing pressures.

Via The Motley Fool

Viking Therapeutics: The High-Stakes Weight Loss Contender ↗

February 26, 2026

Via MarketBeat

Eli Lilly's New Oral Weight Loss Drug Outperforms Semaglutide, Eyes Potential US Approval In Q2 ↗

February 26, 2026

Eli Lilly shares rise after orforglipron beats Novo's drug in Phase 3, cutting A1C by 2.2% and boosting weight loss results.

Via Benzinga

The Darwinian Transition: AI Monetization and Metabolic Mastery Define the Market’s New Frontier

February 26, 2026

As the final week of February 2026 draws to a close, the financial markets have emerged from what analysts are calling the most consequential “Heavyweight Week” of the post-pandemic era. The...

Via MarketMinute

Topics Artificial Intelligence Economy

Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy

February 26, 2026

In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI...

Via MarketMinute

Topics Economy Intellectual Property

Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026

February 26, 2026

As of February 26, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at the center of one of the most polarized debates in the modern healthcare sector. Once the "poster child" of the 2024-2025...

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

Alphabet Inc. (GOOGL) Deep Dive: Navigating the Agentic Era and the $180 Billion AI Bet

February 26, 2026

As of February 26, 2026, Alphabet Inc. (NASDAQ: GOOGL) stands at a defining crossroads in its nearly three-decade history. Long the undisputed gatekeeper of the internet’s information, the Mountain...

Via Finterra

Topics Artificial Intelligence Initial Public Offering Workforce

Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore ↗

February 26, 2026

How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think.

Via The Motley Fool

Eli Lilly’s Diabetes Pill Outperforms Oral Semaglutide in Phase 3 Trial ↗

February 26, 2026

Investors are closely watching the oral GLP-1 race as competition intensifies across the sector.

Via Stocktwits

Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow

February 25, 2026

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results this Friday morning. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies ↗

February 25, 2026

Investors weigh steep GLP‑1 price cuts against a multibillion‑dollar oral obesity push, fresh analyst caution, and a new partnership, today, Feb. 25, 2026.

Via The Motley Fool

Topics Stocks

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.